Actively Recruiting
Evaluating Safety of Ex Vivo Corneal Cross Linking in Vascularized High-Risk Penetrating Keratoplasty Across Multiple Centers
Led by Massachusetts Eye and Ear Infirmary · Updated on 2026-09-21
96
Participants Needed
12
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a randomized, double-masked, multi-site clinical trial to evaluate the safety of Ex Vivo Corneal Cross Linking CXL of donor corneal tissue in people who have undergone high-risk penetrating keratoplasty. This study focuses on patients with corneal transplant failure characterized by significant corneal neovascularization. The trial aims to assess whether treating donor corneal tissue with CXL affects the safety of transplantation over a 24-month period. Participants are randomly assigned to receive either donor corneal tissue treated with 0.1% riboflavin Vitamin B2 and 20% dextran Photrexa Viscous & Photrexa with UV light exposure or untreated tissue without UV treatment. The treated tissue is prepared by a Corneal Tissue Bank according to current good tissue practices and then transplanted by participating institutions. The study compares outcomes between these two groups to determine any differences related to the cross-linking procedure. During the study, participants will be monitored for up to 24 months after their transplant to track adverse events and evaluate graft success. Assessments include safety measures, rates of graft failure, time to graft failure or rejection, and image-based evaluations of corneal tissue. This long-term follow-up helps researchers understand the impact of cross-linking on transplant outcomes and patient safety over time.
CONDITIONS
Brief Title
ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty
Research Team
M
Michael Cheung, MSc, CCRP
N
Nikolay Boychev, OD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here